Boehringer Ingelheim

SPEVIGO

Manufacturer:

Boehringer Ingelheim

Spevigo HCPCS:

J1747

HCPCS Code Descriptor:

Injection, spesolimab-sbzo, 1 mg

Category:

J Code

Spevigo NDCs:

00597-0035-10

Primary Type:

Unclassified

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00597-0035-10

About Spevigo:

SPEVIGO is an Unclassified drug manufactured by Boehringer Ingelheim and administered via the Intravenous route of administration. The J Code: J1747 is aligned to the drug SPEVIGO.

ACCESS PRICING AND MORE BY REGISTERING

J1747 Added Date:

April 1, 2023

J1747 Effective Date:

April 1, 2023

J1747 Termination Date:

HCPCS Active

Spevigo billing and coding information can be found through Boehringer Ingelheim at the link below:
Our team did not identify a source for Spevigo patient assistance information. Please reach out to our team if you feel that this is a mistake.
SPEVIGO prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for SPEVIGO. Please check back in a few weeks.